- Home
- NCMI vs PRME Comparison
NCMI vs PRME Comparison
Compare NCMI & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCMI | PRME |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 414.7M | 601.1M |
| IPO Year | 2007 | 2022 |
Fundamental Metrics
Financial Performance| Metric | NCMI | PRME |
|---|---|---|
| Price | $4.09 | $4.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $6.88 | ★ $9.31 |
| AVG Volume (30 Days) | 417.5K | ★ 3.7M |
| Earning Date | 10-30-2025 | 11-07-2025 |
| Dividend Yield | ★ 2.89% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $236,300,000.00 | $5,977,000.00 |
| Revenue This Year | $3.66 | $111.80 |
| Revenue Next Year | $12.17 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 647.13 |
| 52 Week Low | $3.81 | $1.11 |
| 52 Week High | $7.60 | $6.94 |
Technical Indicators
Market Signals| Indicator | NCMI | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 46.27 | 52.01 |
| Support Level | $4.06 | $3.95 |
| Resistance Level | $4.25 | $4.42 |
| Average True Range (ATR) | 0.13 | 0.30 |
| MACD | 0.00 | 0.12 |
| Stochastic Oscillator | 22.22 | 76.72 |
Price Performance
Historical ComparisonAbout NCMI National CineMedia Inc.
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.